The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study. MSD has revealed that the National Institute for Health and Care Excellence (NICE) has recommended the use of Keytruda. Also known as pembrolizumab, the therapy treats tumours with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). It also involves adults with advanced or recurrent endometrial cancer that has progressed during or after platinum-based therapy, as well as certain patients with gastric, small intestine or biliary cancer…
Last we heard from U.K. cell therapy biotech Celixir in July 2020, the COVID-19 pandemic had stymied an ongoing clinical trial of its cardio cell therapy and the hope was that recruitment could continue in the third quarter of 2020…
Three-and-a-half years since SARS-CoV-2 spread around the world, scientists are still documenting the virus’ myriad effects on human health. What’s clear already is that those effects can continue long beyond the original infection. Now, researchers have attempted to quantify this long-term harm using a massive database of U.S. veterans’ health records. They found a dramatically increased risk of dozens of conditions including heart failure and fatigue, sometimes years postinfection. Overall, the team estimates, COVID-19’s public health impact is more than 50% greater than that of cancer or heart disease…